We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

InhibOx and COSMIC Discoveries Align to Deliver Full Service Drug Discovery Offering

InhibOx and COSMIC Discoveries Align to Deliver Full Service Drug Discovery Offering

InhibOx and COSMIC Discoveries Align to Deliver Full Service Drug Discovery Offering

InhibOx and COSMIC Discoveries Align to Deliver Full Service Drug Discovery Offering

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "InhibOx and COSMIC Discoveries Align to Deliver Full Service Drug Discovery Offering"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

InhibOx Ltd and the COSMIC Discoveries have announced that they have formed a close strategic partnership to deliver a full service drug discovery service offering, incorporating expert computational, medicinal and synthetic chemistry design capabilities.

Both commercial organizations, linked to world-leading academic institutes, have built their services on advanced proprietary science and technology. Together, they offer unique capabilities that are able to address the most demanding drug discovery challenges on behalf of biotech and pharmaceutical companies worldwide.

Computational chemistry service organizations tend to operate in isolation, leaving their customers to handle compound acquisition or synthesis. Similarly, medicinal chemistry providers often use standard, off-the-shelf molecular modeling systems and databases, with only a small team of specialist users - they therefore lack access to advanced, proprietary systems and breadth of expertise.

This partnership meets the market need to bring to the customer a single point of business contact and ownership and to deliver joined-up leading-edge design services.

InhibOx, the computational drug discovery specialist, is pioneering the use of cloud computing to offer rigorous, full-spectrum computer-aided drug discovery capabilities to customers around the world. COSMIC Discoveries’ diverse medicinal and synthetic chemistry expertise spans major therapeutic areas and numerous disease-relevant targets and mechanisms.

Their medicinal and computational chemists have developed multiple pre-clinical drug candidates from early leads and hits in a wide variety of therapeutic areas.

“InhibOx is extremely proud to enter into partnership with such a prestigious research establishment, led by Professor Iqbal. Their medicinal and synthetic chemistry insights give InhibOx the scope not only to design lead libraries but to deliver samples built from innovative, well-validated chemistries,” said Professor Graham Richards, chairman & founder of InhibOx and former chairman of chemistry at Oxford University. “This is exciting because it effectively broadens the accessible chemistry space for our customers to include the 110 million compounds in our Scopius platform – the world’s largest available curated drug candidate database. This is truly innovative, integrated design and build services at scale.”

Professor Javed Iqbal, president & founder of COSMIC Discoveries and former distinguished research scientist and global head, discovery chemistry at Dr Reddy’s laboratory, explained, “This strategic partnership allows COSMIC Discoveries to offer design and build services based on a far more diverse set of starting propositions, derived from an innovative and wider chemistry space, tuned to our unique synthetic and medicinal chemistry capabilities. The access this partnership gives us to InhibOx’s powerful and unique in silico design capabilities sets COSMIC Discoveries apart from standard chemistry suppliers”.

The two organizations, in addition to offering integrated drug discovery services, will collaborate on the design of new candidate molecules in support of an internal research projects at Cosmic Discoveries.